Article | Published:

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

Nature Medicinevolume 4pages232234 (1998) | Download Citation

Subjects

Abstract

Malignant melanoma is a prime example of cancers that respond poorly to various treatment modalities including chemotherapy1. A number of chemotherapeutic agents have been shown recently to act by inducing apoptosis, a type of cell death antagonized by the bcl-2 gene2. Human melanoma expresses Bcl-2 in up to 90% of all cases3–7. In the present study we demonstrate that bcl-2 antisense oligonucleotide treatment improves the chemo-sensitivity of human melanoma grown in severe combined im-munodeficient (SCID) mice. Our findings suggest that reduction of Bcl-2 in melanoma, and possibly also in a variety of other tumors, may be a novel and rational approach to improve chemosensitivity and treatment outcome.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Boring, C.C., Squires, T.S., Tong, T. & Montgomery, S. Cancer statistics 1994. CA: Cancer J. Clinic 44, 7–26 (1994).

  2. 2

    Hickman, J.A. Apoptosis and chemotherapy resistance. Eur. J. Cancer 32A, 921–926 (1996).

  3. 3

    Cerroni, L., Soyer, H.P. & Kerl, H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am. J. Dermatopathol. 17, 7–11 (1995).

  4. 4

    Morales-Ducret, C.R.J., van deRijn, M., LeBrun, D.P. & Smoller, B.R. bcl-2 expression in primary malignancies of the skin. Arch. Dermatol. 131, 909–918 (1995).

  5. 5

    Plettenberg, A. et al. Human melanocytes and melanoma cells constitutively express the Bcl-2 proto-oncogene in situ and in cell culture. Am. J. Pathol. 146, 651–659 (1995).

  6. 6

    Tron, V.A. et al. Immunohistochemical analysis of Bcl-2 protein regulation in cutaneous melanoma. Am. J. Pathol. 146, 643–650 (1995).

  7. 7

    Grover, R. & Wilson, C.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 22, 347–349 (1996).

  8. 8

    Stein, C.A. & Cheng, Y.-C. Antisense oligonucleotides as therapeutic agents–Is the bullet really magical? Science 261, 1004–1012 (1993).

  9. 9

    Stein, C.A. Does antisense exist? Nature Med. 1, 1119–1121 (1995).

  10. 10

    Christoffersen, R.E. Translating genomics information into therapeutics: A key role for oligonucleotides. Nature Biotechnol. 15, 483–484 (1997).

  11. 11

    Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med. 2, 668–675 (1996).

  12. 12

    Comis, R.L. DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep. 60, 165–176 (1976).

  13. 13

    Henry, S.P., Monteith, D. & Levin, A.A. Antisense oligonucleotide inhibitors for the treatment of cancer. 2. Toxicological properties of phosphorothioate oligonucleotides. Anti-Cancer Drug Des. 12, 395–408 (1997).

  14. 14

    Krieg, A.M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).

  15. 15

    Wooldridge, J.E., Ballas, Z., Krieg, A.M. & Weiner, G.J. Immunostimulatory oligonucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89, 2994–2998 (1997).

  16. 16

    Webb, A. et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349, 1137–1141 (1997).

Download references

Author information

Affiliations

  1. Department of Clinical Pharmacology, Section of Experimental Oncology, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria

    • Burkhard Jansen
    • , Hermine Schlagbauer-Wadl
    • , Markus Müller
    •  & Hans-Georg Eichler
  2. Department of Dermatology, Division of General Dermatology, University of Vienna, Währinger Gürtel 18-20, A-1090, Vienna, Austria

    • Burkhard Jansen
    • , Hermine Schlagbauer-Wadl
    • , Klaus Wolff
    •  & Hubert Pehamberger
  3. Genta Incorporated, 3550 General Atomics Court, San Diego, California, 92121, USA

    • Bob D. Brown
    •  & Robert N. Bryan
  4. Department of Clinical Oncology, University Hospital (AZL), 2300, Leiden, The Netherlands

    • Andrea Van Elsas

Authors

  1. Search for Burkhard Jansen in:

  2. Search for Hermine Schlagbauer-Wadl in:

  3. Search for Bob D. Brown in:

  4. Search for Robert N. Bryan in:

  5. Search for Andrea Van Elsas in:

  6. Search for Markus Müller in:

  7. Search for Klaus Wolff in:

  8. Search for Hans-Georg Eichler in:

  9. Search for Hubert Pehamberger in:

About this article

Publication history

Received

Accepted

Issue Date

DOI

https://doi.org/10.1038/nm0298-232

Further reading